Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (371-380 of 427) with videos related to

Pageof 43
Sort By:
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Leukemia & Lymphoma|March 28, 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaRuben Niesvizky, Ashraf Z Badros, Luciano J Costa, et al.
Future Oncology (London, England)|September 30, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Pageof 43

Showing results (371-380 of 427) with videos related to

Sort By:
Pageof 43
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Leukemia & Lymphoma|March 28, 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaRuben Niesvizky, Ashraf Z Badros, Luciano J Costa, et al.
Future Oncology (London, England)|September 30, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Pageof 43